Agenus Inc AGEN shares are trading higher by 35.28% at $4.41 Tuesday morning after the company, along with Bristol-Myers, announced an exclusive global license to Agenus' proprietary bispecific antibody program, AGEN1777. Agenus will receive a $200 million upfront payment and up to $1.36 billion in milestone payments.
Agenus is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria and glioblastoma. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells.
See also: How to Buy Stocks
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
